International Journal of Research and Review
[Indexed, Peer-Reviewed Journal]
Volume 12; Issue: 1; January 2025
Website: www.ijrrjournal.com
Review Paper *E-ISSN: 2349-9788; P-ISSN: 2454-2237*

A Review on Thermal and Electrical Hazards in the Pharmaceutical Industry

Aishwarya R Ghanwat[1], Kumudini R Pawar[2], Krutika S Nilwani[3], Shital P Narwade[4], Pratibha L Ayanar[5]

Abhinav Education Society's, College of Pharmacy (B. Pharm), Narhe, Pune, 411041, Maharashtra, India.

Corresponding Author: Dr. Kumudini R Pawar

DOI: https://doi.org/10.52403/ijrr.20250150

ABSTRACT

Thermal and electrical hazards in the pharmaceutical industry pose a significant risk to operational safety, product integrity, and regulatory compliance. These risks arise from the high-temperature processes of exothermic reactions, electrostatic discharge, and electrical system malfunctions. As advanced technologies in continuous manufacturing and high-speed automation are increasingly integrated, the complexity and magnitude of these hazards are accelerating. According to research findings, thermal and electrical breakdowns represent over 60% of accidents in this sector, an aspect that emphasizes the greater need for advanced safety techniques. This paper compiles all current information that would define the causes and implications of hazards in this review. This focuses on many often neglected critical factors, including high energy content in processes, the volatile nature of solvents, and inadequately developed safety systems. The latest innovations in hazard mitigation, such as predictive maintenance using IoT-enabled sensors, dynamic thermal management systems, and AI-based fault detection algorithms, have demonstrated good potential for reducing incident rates. Additionally, adherence to evolving standards like ISO 45001 and advanced Occupational Safety and Health Administration (OSHA). compliance frameworks are essential for addressing these risks effectively. This review underscores the need to integrate advanced safety technologies and robust risk management frameworks by identifying gaps in current safety practices and proposing evidence-based strategies for ensuring sustainable and compliant pharmaceutical operations.

Keywords: Thermal Hazards, Electrical Hazards, Pharmaceutical Industry Safety, Workplace Hazards in Pharma, Occupational Safety in Pharmaceuticals, Industrial Electrical Safety

INTRODUCTION

The pharmaceutical industry is an area of precision and adherence to very high standards of safety. The thermal and electrical hazards are omnipresent in such an environment and require careful management. Thermal hazards are risks resulting from excessive heat generation, uncontrolled exothermic reactions, or high-temperature processes. These are direct consequences of the energy-intensive nature of pharmaceutical manufacturing. These risks can cause equipment overheating, fires, or explosions, especially in facilities that handle flammable solvents or reactive chemicals. Electrical risks, which include the dangers of short circuits, static

discharge, or equipment malfunction, also present a double threat of workplace accidents and product contamination. Both types of risks are exacerbated by the increasing complexity of manufacturing systems, which integrate high-speed machinery, continuous processing, and automation technologies. The relevance of thermal and electrical hazards in the pharmaceutical industry cannot be overstated(1). According to industry reports, thermal incidents account for nearly 40% of industrial accidents in the chemical and pharmaceutical sectors, and improper control of thermal conditions during synthesis or drying operations is usually a leading cause. Electrical hazards account for about 25% of the injuries in the workplace, with static electricity posing a huge risk in low-humidity environments and high flammability. These hazards not only endanger the workers but also bring about huge economic losses through production downtime, regulatory penalties, and damaged infrastructure. They also compromise product integrity, resulting in recalls that tarnish the brand reputation and consumer trust. In pharmaceutical production, there are several critical operations where thermal hazards manifest. For example, in a tablet compression or API synthesis process, the amount of developed heat may surpass safe limits without proper cooling or temperature regulation(2). Other exothermic reactions that release heat through the chemical reaction itself may pose significant risks for thermal runaway, or unregulated heat development propels chemical reaction rates resulting in cataclysmic explosions. In such state-of-the-art automation centers for pharmaceuticals, electrical dangers are common and often seen in advanced structures. Electrical arcs and lack of proper insulation along with overloading circuits create severe and possible equipment failure with easy potential ignition of flammable objects nearby, increasing hazards times more. Widespread uses of solvents as ethyl alcohol, acetone, and other VOC make it more challenging: small sparks from static charges will trigger devastating fires and possible explosions. This review aims to consolidate existing knowledge on thermal and electrical hazards, analyze their implications, and propose practical solutions to mitigate these risks. The first objective is to provide a comprehensive understanding of the origins and mechanics of these hazards, integrating insights from recent industrial case studies and research. The second aim of the review is to identify the existing gaps within hazard management, including limited real-time monitoring systems or failure to integrate predictive analytic into safety protocols. In this way, deficiencies in these areas are highlighted, as the review stresses the incorporation of advanced technologies, for example, IoT-enabled sensors for continuous monitoring, advanced thermal imaging systems for early detection of faults, and AI-driven predictive maintenance tools(3). Furthermore, this review promotes regulatory frameworks, such as ISO 45001 and OSHA standards that would provide a minimum standard for safety controls by calling for industry-based adaptations of best practices pertinent to pharmaceutical operations. Presenting this summary of scientific evidence, it would help stakeholders navigate how best to adopt active and proactive risk management in their areas of pharmaceutical operation. Ultimately, the removal of thermal and electrical hazards is not only an obligation but a critical requirement in the creation of safe, efficient, and sustainable pharmaceutical manufacturing processes. In conclusion, the highly interactive nature of the pharmaceutical industry makes the use of energy-intensive processes, reactive chemicals, and sophisticated machinery require more than just the removal of these hazards(4). This review aims to close the gap between theory and practice and help stakeholders apply knowledge toward increasing safety, regulatory compliance, and personnel and product protection. The industry can leverage the use of emerging technologies, along with a culture of

continuous improvement, to reduce the identified risks and stay committed to operational excellence and safety.

MATERIALS & METHODS

Overview of the Pharmaceutical Industry

The pharmaceutical industry involves a series of highly controlled and specialized processes that are aimed at ensuring the safety, efficacy, and quality of drug products. The most important stage in the sequence are chemical synthesis, which involves creating active pharmaceutical ingredients (APIs) under high temperatures and pressures, often with exothermic reactions. Formulation processes, such as granulation, mixing, and drying, use machinery that produces considerable heat and can pose thermal hazards. Sterilization is another critical step, especially for injectables and surgical products, and involves high-temperature equipment like autoclaves, which can pose risks of burns and overheating. Furthermore, automated packaging operations, like blister packaging, involve machinery powered by electrical systems, which might malfunction or create electrical hazards if not maintained properly (5).

Table 1: Equipment and Associated Hazards in Pharmaceutical Manufacturing

Equipment	Thermal Hazards	Electrical Hazards
Reactors	Exothermic reactions, overheating	Static electricity, faulty wiring
Dryers	High surface temperatures, risk of fires	Overloading of circuits
Autoclaves	High-pressure steam, burns, risk of explosion	Malfunctioning electronic controls
Mixers	Heat generated during prolonged operation	Improper grounding
Powder Handling Units	Risk of dust explosions due to heat sources	Static discharge leading to ignition
HVAC Systems	Overheating of compressors	Electrical short circuits in control systems
Packaging Machines	Heat from sealing operations	Electrical faults in automated systems

Overview of Equipment and Infrastructure Prone to Hazards

Pharmaceutical manufacturing facilities have various machines and systems prone to thermal and electrical hazards. For example, a chemical synthesis reactor can get too hot during an exothermic reaction and build static electricity, especially if not well grounded. Dryers, which remove moisture from materials, run above 150°C, at which temperature residual solvent vapors can ignite, potentially setting a fire(6). Similar cases include HVAC systems, which maintain environmental conditions and tend to overheat in the event of compressor failure while the electrical components are likely to have short circuits. Electrical faults can also occur with packaging machines that make use of heat-sealing processes and automated controls. The frequency of hazard study reveals that 35% of the incidents occur during the synthesis of chemicals, followed by 25% in drying processes, 20% in packaging operations, and 20% in other activities. This calls for high standards of safety at all manufacturing stages (7). These insights emphasize the need for targeted strategies to mitigate hazards, such as improved insulation, regular equipment maintenance, and advanced safety monitoring systems. By addressing these risks, the pharmaceutical industry can enhance operational safety and prevent accidents that compromise worker safety and product quality.

Thermal Hazards

Thermal hazard in the pharmaceutical industry occurs from several different processes and activities that generate or inadequately handle heat, which sometimes can lead to accidents, degradation of the product, and sometimes catastrophic incidents. The main source of these thermal

hazards is exothermic reactions involving chemical synthesis, accounting for 45% of these thermal hazard incidents(8). These reactions, by nature, occur in the manufacture of APIs and entail significant amounts of heat release if not controlled can lead to thermal runaway. A widely reported case involves the synthesis of a bulk API at a pharmaceutical plant in India. In this case, an uncontrolled temperature rise resulted from poor cooling during a nitration reaction, leading to an explosion that damaged equipment and hurt workers(9). This example calls for the implementation of highly accurate thermal monitoring systems along with contingency protocols. Thermal hazards account for 35% of heat from industrial equipment such as dryers, reactors, and autoclaves. Fluidized bed dryers are used for the removal of moisture from the pharmaceutical materials, and these dryers operate at temperatures above 150°C. This poses a risk of ignition for solvent-laden compounds during processing. In 2018, a fire at a pharmaceutical plant in China occurred due to the overheating of the dryer during the processing of flammable solvents. It happened due to poor maintenance and the absence of heat-sensing alarms, causing considerable material loss and operational downtime. Similarly, autoclaves, essential for sterilization, operate at high-pressure steam temperatures between 121°C and 134°C, posing burn risks and explosion hazards when improperly maintained(10).

Storage and handling of heat-sensitive material, which account for 20% of thermal hazards, are other challenges. Many APIs and excipients degrade or destabilize with increased temperatures; thus strict environmental controls are required to handle them. One was the case at a pharmaceutical plant in Europe, whose improper storage conditions led to the thermal degradation of an insulin batch, causing this firm losses amounting to more than $2 million and delays in supply. Investigations showed that a faulty HVAC system was unable to maintain the required storage temperature below 30°C(10,11). These case studies show common failures in managing thermal hazards, such as inadequate temperature monitoring, poor equipment maintenance, and improper storage protocols. They illustrate the need to establish adequate safety controls, including the installation of state-of-the-art thermal sensors that can trigger a shut-off system and prevent overheating, routine servicing of such equipment that works at high temperatures, and employee training on response to emergencies and hazard identification. With this, pharma plants can significantly reduce the risks and severity of thermal hazard events and protect employees as well as the quality of the product(12).

Risk Assessment and Prevention Strategies

Electrical hazards are serious in the pharmaceutical industry due to the possibility of compromise to employees' safety, destruction of equipment, and possible disruptions in production. Proper solutions for these hazards would thus be a multi-factor approach, including risk assessment and putting in place strict preventive measures. A systematic process helps in risk identification, risk analysis, and risk reduction, hence ensuring efficiency and protecting people. Risk assessment starts with Hazard Identification (HAZID), a stepwise procedure for the identification of potential electrical hazards. It includes dangers from exposed wiring, malfunctioning equipment, or generation of static electricity during powder processing common in pharmaceutical operations(13). From there, Fault Tree Analysis maps the sequence of events leading to an electrical accident. This method helps pinpoint the root causes of failures and highlights weak points in safety systems. After FTA, a Risk Matrix is used to prioritize the identified hazards by categorizing them based on the likelihood of occurrence and the severity of their consequences. By systematically evaluating these risks, high-priority

scenarios, such as potential fires or catastrophic equipment failures, can be addressed with urgency, ensuring that critical hazards are not overlooked. Prevention and mitigation measures are equally crucial for reducing electrical hazards. These strategies begin with the establishment of robust safety protocols tailored to the unique requirements of thermal and electrical equipment used in pharmaceutical manufacturing. Regular training programs ensure that personnel understand the operation and handling of high-voltage machinery and are aware of the risks posed by static electricity. Maintenance plays an important role in ensuring safety with electrical equipment(14). Among its many roles, such as conducting periodic inspections for electrical systems, identifying wear and tear, and performing timely repair, it replaces deteriorated components like insulation. Proper grounding systems and high-grade wiring also prevent electrical failures. Advanced safety equipment, for example, thermal sensors which detect overheating, as well as circuit breakers that mitigate electrical surges, add layers of safety against accidents. Anti-static measures are essential in environments in which fine powders are dealt with. Pharmaceutical manufacturing often involves processes that generate significant static electricity, posing risks of explosions or fires in the presence of flammable substances(15). To mitigate this, facilities must adopt solutions such as conductive flooring, proper grounding techniques, and the use of anti-static agents. Explosion-proof equipment and controlled humidity systems further reduce the likelihood of incidents. Lockout/tagout (LOTO) procedures during maintenance activities ensure that equipment remains de-energized, preventing accidental activation and safeguarding workers. Automation and advanced technologies are changing the face of electrical hazard prevention in modern pharmaceutical facilities. Real-time safety monitoring systems equipped with advanced sensors can detect anomalies such as voltage fluctuations, overheating, or the buildup of static electricity, providing early warnings before hazards escalate. These systems allow for immediate corrective actions, thereby minimizing risks and reducing downtime. Predictive maintenance is a huge leap forward in hazard prevention and is highly dependent on the capabilities of the Internet of Things (IoT) and Artificial Intelligence (AI). IoT sensors continuously monitor the condition of equipment, collecting data on critical parameters such as motor vibrations, insulation resistance, and temperature variations(16). The AI algorithms go through the information and try to spot the underlying patterns, such as performance degradation or failures. Some subtle variations in motor vibration or the quality of the insulation will call for alarm systems to anticipate preventive actions, avoiding breakdowns in equipment and its corresponding dangers. Automation and technology in this line also promote greater efficiency and productivity. By addressing potential issues before they escalate, facilities can reduce unplanned downtime, lower maintenance costs, and improve productivity. A comprehensive safety culture, supported by regular training, advanced technologies, and a proactive approach to risk management, ensures a safer working environment. This approach safeguards personnel, protects assets, and maintains the continuity of operations in pharmaceutical settings, underscoring the importance of investing in electrical hazard prevention and mitigation strategies(17,18). The pharmaceutical industry can better address the complex challenges posed by electrical hazards by combining traditional safety practices with cutting-edge technology, thus ensuring long-term sustainable and safe operations(19).

Regulatory Framework and Guidelines

The regulatory framework and guidelines governing safety in pharmaceutical manufacturing play a pivotal role in ensuring the well-being of personnel, the protection of assets, and the production of

high-quality pharmaceuticals. These frameworks encompass a comprehensive set of international and local regulations, standards, and best practices aimed at minimizing risks and maintaining compliance with safety requirements. The dynamic nature of pharmaceutical manufacturing, coupled with the potential hazards associated with processes involving thermal and electrical equipment, makes adherence to these regulations essential for sustainable operations. Globally, various regulatory bodies have established safety standards to address the unique. challenges of the pharmaceutical industry. Organizations such as the Occupational Safety and Health Administration (OSHA), the International Electrotechnical Commission (IEC), the National Fire Protection Association (NFPA), and Good Manufacturing Practices (GMP) provide foundational guidelines to promote workplace safety and ensure product integrity. OSHA, for instance, emphasizes the importance of creating a safe working environment through its standards for electrical safety, hazard communication, and personal protective equipment. OSHA mandates that employers assess workplace hazards, implement control measures, and provide training to workers to prevent accidents and injuries(20). The IEC, on the other hand, focuses on standardizing electrical equipment and practices to ensure safety and efficiency. IEC standards, such as IEC 60364 for electrical installations in buildings, are critical in preventing electrical hazards in pharmaceutical facilities. Similarly, the NFPA has developed codes and standards, such as NFPA 70 (National Electrical Code) and NFPA 654 (Standard for the Prevention of Fire and Dust Explosions), that address fire prevention and control in industrial settings. These standards are particularly relevant to pharmaceutical manufacturing, where flammable chemicals and combustible dust are common. Good Manufacturing Practices (GMP) are integral to pharmaceutical safety and quality assurance. GMP guidelines emphasize the need for controlled environments, validated processes, and robust documentation to ensure consistent product quality and compliance with safety standards. GMP also underscores the importance of regular maintenance of equipment, adherence to safety protocols, and the implementation of risk-based approaches to manage potential hazards. These principles align with broader regulatory requirements, fostering a culture of safety and accountability in pharmaceutical manufacturing(21).

Despite the availability of comprehensive guidelines, compliance with safety regulations poses significant challenges for the pharmaceutical industry. One primary challenge is the complexity and variability of regulatory requirements across different regions. While international standards provide a unified framework, local regulations often introduce additional layers of compliance, leading to potential inconsistencies and increased administrative burdens. Pharmaceutical manufacturers operating in multiple countries must navigate these discrepancies, adapting their practices to meet diverse regulatory expectations. Another challenge lies in the dynamic nature of the pharmaceutical industry, characterized by rapid technological advancements and the introduction of innovative processes(22). Emerging technologies, such as continuous manufacturing and advanced automation, often outpace the development of regulatory guidelines, creating uncertainty for manufacturers striving to remain compliant. Integrating these technologies into existing frameworks requires significant investments in training, infrastructure upgrades, and ongoing collaboration with regulatory authorities. The evolving landscape of electrical and thermal presents additional hurdles. The increasing reliance on complex machinery and high-energy systems necessitates regular updates to safety protocols and equipment standards. Ensuring compliance with these evolving requirements demands continuous

monitoring, routine inspections, and investments in state-of-the-art safety measures. For example, the implementation of advanced safety technologies, such as predictive maintenance systems and real-time monitoring tools, requires alignment with regulatory expectations and adherence to certification standards. Moreover, maintaining a culture of compliance within organizations can be challenging, particularly in facilities with diverse operational teams. Ensuring that all personnel are well-versed in safety regulations and committed to following best practices requires ongoing training, clear communication, and leadership commitment. Resistance to change, insufficient resources, and competing priorities often hinder the effective implementation of safety measures. To address these challenges, pharmaceutical manufacturers must adopt proactive strategies to strengthen compliance. Regular audits, both internal and external, are essential for identifying gaps in safety practices and ensuring adherence to regulatory requirements. Establishing robust communication channels with regulatory authorities fosters collaboration and enables manufacturers to stay informed about updates and emerging trends. Leveraging digital solutions, such as compliance management software and automated documentation systems, can streamline the regulatory process, reduce administrative burdens, and enhance transparency. Additionally, fostering a safety-centric culture within organizations is crucial(23). Leadership must prioritize safety as a core value, ensuring that resources are allocated to training programs, equipment upgrades, and the implementation of best practices. Encouraging employee engagement through safety awareness campaigns, recognition programs, and feedback mechanisms can further reinforce compliance and accountability. In conclusion, the regulatory framework and guidelines governing safety in pharmaceutical manufacturing are indispensable for ensuring a secure and efficient working environment. International standards from organizations like OSHA, IEC, NFPA, and GMP provide a robust foundation for managing risks and promoting best practices(24). However, compliance challenges, including regulatory variability, technological advancements, and operational complexities, require a proactive and adaptive approach. By investing in advanced safety technologies, fostering a culture of compliance, and maintaining active engagement with regulatory authorities, pharmaceutical manufacturers can navigate these challenges effectively. This approach not only enhances safety but also supports operational excellence and the production of high-quality pharmaceuticals, aligning with the industry's commitment to public health and safety(25).

Role of Training and Safety Culture

Training and safety culture have a very important role in preventing accidents, minimizing risks, and creating a safe working environment for pharmaceutical manufacturing facilities. No amount of words can do justice to the importance of worker training on hazard identification and response, coupled with the development of a strong safety culture. Proper training enables employees to be aware of and respond promptly to possible hazards, which in turn minimizes the chances of incidents. In addition, an organization's culture of safety fosters awareness, accountability, and proactive behavior among workers, which ensures that safety is a top priority at all levels of operation. One of the most important elements of a comprehensive safety program is worker training. This aspect forms a major step in hazard detection-whether electrical, thermal, mechanical, or chemical. Hazard detection training in employees serves as the only means for accident prevention. Pharmaceutical manufacturing facilities have highly complex operations requiring great accuracy and sense of safety. Workers have to be trained in detecting glaring, along with less glaring risks including

malfunctioning machinery, electric current shorts, overheating, exposure to dangerous chemicals or static buildup in powder handling areas(26). Well-trained employees in the identification of hazards will be able to respond to dangers promptly and effectively. Regular training programs should be conducted to ensure that workers are updated on the latest safety protocols, techniques for hazard identification, and emergency response procedures. In addition, training should be on how to use personal protective equipment (PPE), handle hazardous materials, and operate equipment safely, thus mitigating risks in daily operations. In addition to hazard identification, training includes proper actions for responses to emergencies. Workers should be provided with training to use emergency equipment like fire extinguishers, circuit breakers, and first aid kits, and be educated on how quickly and effectively to evacuate the facility in the occurrence of a crisis. This can be achieved through emergency response drills, simulating different scenarios, such as electrical fires or chemical spills. Through frequent practice of these responses, workers become more confident and capable of handling real-life situations effectively. Moreover, workers should be encouraged to report hazards or unsafe practices to foster an environment of transparency and continuous improvement. In parallel with training, developing a culture of safety within the organization is equally important. A safety culture is the type of environment where safety is incorporated in every aspect of the organization, from top management to front-line workers. Such a culture promotes shared responsibility for safety and encourages proactive behavior(27). Leadership is essential in setting the tone for safety practices. When management demonstrates a consistent commitment to safety, communicates the importance of safety, and leads by example, it creates an environment in which employees feel empowered and motivated to take safety seriously. Senior management should be active participants in safety meetings, advocate for adequate resources to support safety initiatives, and visibly be involved in safety efforts. This involvement sends a strong message that safety is a core organizational value and not merely a regulatory requirement. The implementation of a safety culture needs transparent communication, and safety policies which need to be easily understood by everyone in the organization and be accessible to all workers. These policies need to be reviewed and updated continually based on changes in regulatory and technological requirements and organizational operational practices. A well-embedded safety culture also encourages workers to participate in safety programs and express their observations and ideas that would improve the situation. An organization engages employees actively through safety initiatives and, therefore builds a sense of ownership of the safe working environment of the collective responsibility to have a safe work environment. Incident reporting is also an essential part of fostering a safety culture. Incident reporting is the reporting of accidents, near-misses, and other unsafe conditions by workers in a non-punitive environment. By encouraging employees to report incidents or potential hazards, organizations can identify patterns, pinpoint root causes, and take corrective actions to prevent future occurrences(28). An effective incident reporting system should be simple, accessible, and confidential, ensuring that employees feel safe and supported when reporting issues. In addition to reporting accidents, workers should be encouraged to report near-misses—incidents that could have led to accidents but did not. Reporting near misses is an invaluable tool to identify and address hazards before they cause actual harm and hence improve the overall safety. Once incidents are reported, it is very important for the organization to take prompt and effective corrective measures. The incident investigations should be done properly so that the underlying causes are

understood whether they relate to human error, equipment failure, inadequate training, or lapses in safety protocols. The results of these studies must be applied in the areas of prevention through updating procedures on safety, improving the training programs, or acquiring more advanced equipment. A sound safety culture is only strengthened by continuous improvement. Safety should never be considered an absolute goal but a process of continued learning and evolution. Regular audits, risk assessment, and feedback from the worker will be able to know areas for improvement and ascertain that safety measures are current and effective. Safety performance should be monitored and measured regularly to assess the success of safety programs and training activities. Some of the KPIs used to measure safety include incident rates, near-miss reports, and compliance with safety protocols. Such performances with safety should be rewarded for improving the standard of safety in a workplace. Recognition and incentive programs for safe behaviors encourage employees to remain vigilant and committed to safety. Training and culture of safety are very necessary measures for preventing accidents and keeping up with a safe working environment at pharmaceutical manufacturing. With employee training in the identification of hazards and response to emergencies, an organization develops an organizational culture that enables workers to behave proactively and responsibly. An incident reporting system combined with a process for continuous improvement provides more opportunities to recognize hazards and make appropriate corrections. Commitment to Safety, with training and open lines of communication, and inclusion of leadership, protects more than just the workers as it strengthens operational efficiency along with regulatory compliance. When pharmaceutical companies emphasize training in order to foster a safety-sensitive culture, they minimize risks and, above all, ensure safe working conditions for their employees(29).

Future Directions

Emerging technologies, innovation in material and equipment design, and continued research into safety protocols are shaping the future of hazard prevention in pharmaceutical manufacturing. As the industry progresses, advancements like AI, machine learning, and IoT are expected to make hazard detection more efficient, predictive maintenance better, and operational safety increased. AI, for instance, can predict possible risks before they occur by analyzing data from a variety of sources, including equipment sensors and incident reports. With this predictive ability, pharmaceutical manufacturers can prevent such accidents by ensuring that equipment is serviced and re-calibrated in advance(30). This, in turn, reduces the chances of equipment failure, which leads to accidents. The IoT significantly contributes to enhancing safety as it involves the integration of sensors into equipment, machinery, and personal protective gear. These sensors continuously monitor factors such as temperature, humidity, and electrical load, providing real-time alerts in case of anomalies. Such data can also facilitate predictive maintenance, as sensors can detect early signs of equipment failure, allowing for timely repairs and minimizing the risk of accidents. Additionally, IoT devices can improve communication across departments and track safety performance, ensuring informed decision-making and rapid response to potential hazards. Innovations in material and equipment design are also helping to produce safer pharmaceutical manufacturing environments. For example, new, better-insulating materials are being designed to prevent the electrical hazards of fire(31). In addition, anti-static materials and explosion-proofing of equipment are enhancing safety in environments dealing with flammable chemicals and powders. Equipment design is changing to improve ergonomic design features, such as automatic shutoff mechanisms, remote operation, and user-friendly interfaces. All of these

improvements can make the operators respond in emergency conditions much faster than otherwise possible, thus lessening the chance of human error. There are still some research gaps in the area of hazard prevention, including one major gap related to the role of human behavior in safety. While technology can reduce risks, human error is still a leading contributor to accidents. There may be research into human-machine interfaces (HMIs) and better safety system designs to reduce errors caused by operator fatigue, distraction, or lack of training. More comprehensive safety regulation research is also required which will keep pace with technologies so that new tools and processes are properly regulated while maintaining safety standards(32,33).

CONCLUSION

From the findings discussed above, it can be seen that thermal and electrical hazards in pharmaceutical manufacturing play a very important role to safeguard workers, protect assets, and ensure the production of quality products. Electrical shock, equipment damage, fire, and exposure to harmful chemicals are some of the many risks faced by the pharmaceutical industry. The integration of safety protocols, worker training, development of a strong safety culture, and adherence to regulatory frameworks are key integral components in preventing accidents. Moreover, emerging technologies like AI, machine learning, and IoT have the power to facilitate predictive hazard detection and, thereby, provide a margin for such risks to be reduced. Meanwhile, innovations in material and equipment design help improve safety working environments through newer materials for insulations, anti-static designs, and equipment resistant to explosions. Proactive management of hazards is very important. Precaution will always be better than cure, and the early identification of hazards prevents further progress of risks once identified into deeper harmful actions. Training workers to identify hazards and develop appropriate responses, along with a corporate culture that emphasizes safety will ensure that safety measures are put in place and followed. Beyond this, incident reporting processes and continuous improvement processes within organizations allow them to apply lessons learned from past activities to improve their practices-a further step toward better safety standards. A proactive approach not only minimizes the chances of accidents but also improves operational efficiency, reduces downtime, and protects the company from financial losses due to accidents or non-compliance. As the pharmaceutical industry continues to evolve with technological advancements, the need for improved safety measures becomes even more critical. This will demand a commitment from the highest levels of an organization—management, employees, and regulatory bodies—to work together in developing a culture of safety. The integration of new technologies should be matched by updated safety protocols so that these innovations are used properly and safely. Manufacturers also need to invest in continuous training, updated equipment, and better monitoring systems to cope with the changing nature of hazards. To move forward, pharmaceutical companies must make safety a priority. This includes engaging actively with emerging technologies, following the regulatory standards, and ensuring that safety is woven into every aspect of manufacturing operations. With proactive hazard management at the forefront, the pharmaceutical industry will continue to advance safety, reduce risks, and improve overall performance for the good of workers and the public.

Declaration by Authors

Ethical Approval: Not Applicable
Acknowledgement: None
Source of Funding: None
Conflict of Interest: No conflicts of interest declared.

REFERENCES

1. Dunn, A. L., Payne, A., Clark, P. R., McKay, C., Williams, G. D., Wheelhouse, K., Arendt, K., Dixon, F., & Shilcrat, S. (2021). Process safety in the pharmaceutical industry: A selection of illustrative case studies. *Journal of Chemical Education*, *98*(1), 175–182. DOI: https://doi.org/10.1021/acs.jchemed.0c00115
2. Chen, Q., Wang, J., Gao, M., Liu, L., & Tao, J. (2022). Review on loss prevention of chemical reaction thermal runaway: Principles and application. *Emergency Management Science and Technology*, *2*(1), 1–8. DOI: https://doi.org/10.48130/emst-2022-0010
3. Zhao, R., Muzzio, D., Vickery, T., Fisher, E., Artino, L., Yin, J., Hinksmon, J., & Fine, A. (2018). Thermal hazard investigation of a pharmaceutical intermediate. *Process Safety Progress*, *37*(2), 263–267. DOI: https://doi.org/10.1002/prs.11917
4. Muneeshwari, P., Suguna, R., Valantina, G. M., Sasikala, M., & Lakshmi, D. (2024). IoT-driven predictive maintenance in industrial settings through a data analytics lens. *2024 International Conference on Trends in Quantum Computing and Emerging Business Technologies*, *7*, 1–5. DOI:10.1109/TQCEBT59414.2024.10545167
5. Hejnaes, K. R., & Ransohoff, T. C. (2018). Chemistry, Manufacture and Control. In *Biopharmaceutical Processing* (pp. 1105–1136). Elsevier. DOI:10.1016/B978-0-08-100623-8.00050-5
6. Chang KC, Chu KC, Chen TL, Lee YLW, Lin YC, Nguyen TT. Study of the High-tech Process Mechanical Integrity and Electrical Safety. In: 2019 14th *International Microsystems, Packaging, Assembly and Circuits Technology Conference* (IMPACT). IEEE; 2019. p. 162–5. DOI:10.1109/IMPACT47228.2019.9024999
7. YK, Murthy L. THE RISK MANAGEMENT APPROACH BY APPLYING HAZARDOUS AREA CLASSIFICATION, WHICH HELPS IN IDENTIFYING THE CRITICAL ZONES IN A PHARMACEUTICAL INDUSTRY. *International Journal of Engineering Science Technologies.* 2023 Sep 9;7(5). DOI:10.29121/ijoest.v7.i5.2023.533
8. Vinayak Vishvanath Londhe, Kalpana S. Deshmukh. Practical approach to prediction and prevention of runaway reactions. *World Journal of Advanced Research and Reviews.* 2022 Nov 30;16(2):139–44. DOI: https://doi.org/10.30574/wjarr.2022.16.2.1137
9. Liu SH, Wang WT, Das M, Shu CM, Wang YR. Investigative calorimetric studies and kinetic parameters estimation using analytical methods for self-reactive hazardous chemicals in a chemical manufacturing plant. J Loss Prev Process Ind. 2022 May; 76:104743. DOI: 10.1016/j.jlp.2022.104743
10. Lefebvre D, Leveneur S. Special Issue on "Thermal Safety of Chemical Processes." Processes. 2021 Jun 17;9(6):1054. DOI:10.3390/pr9061054
11. Alanazi AH. Stability Analysis of Pharmaceutical Preparations under Different Storage Conditions. *Journal of Medical Science and clinical Research.* 2024 Sep 30;12(09):17–20.
12. Kumar N, Jha A. Temperature excursion management: A novel approach of quality system in pharmaceutical industry. *Saudi Pharmaceutical Journal.* 2017 Feb;25(2):176–183. DOI: 10.1016/j.jsps.2016.07.001
13. Floyd HL. Hidden Danger: Reducing Residual Risk in Your Electrical Safety Program. In: 2022 IEEE IAS Electrical Safety Workshop (ESW). IEEE; 2022. p. 1–3. DOI:10.1109/ESW49146.2022.9925026
14. Gordon LB, Martinez TR. A Complete Electrical Risk Assessment Method for all Electrical Hazards and its Application. In: 2018 IEEE IAS Electrical Safety Workshop (ESW). IEEE; 2018. p. 1–8. DOI:10.1109/ESW41044.2018.9063871
15. Presnal J, Houston H, Maberry G. The Electrical Safety Program and the Value in Parterning with Health & Safety Professionals. In: 2020 IEEE IAS Electrical Safety Workshop (ESW). IEEE; 2020. p. 1–7. DOI:10.1109/ESW42757.2020.9188320
16. Bugaris RM. Improving Electrical Safety in the Workplace: Applying Prevention Through Design to Voltage Testing. IEEE Industry Applications Magazine. 2017 May;23(3):12–23. DOI: 10.1109/MIAS.2016.2600724
17. Scarborough MS, Popp JD, Nagl M. Development and integration of an electrical safety program into a new production facility's pre-commissioning and startup activities. In: 2017 IEEE IAS Electrical Safety Workshop (ESW). IEEE; 2017. p. 1–12. DOI:10.1109/ESW.2017.7914836
18. Spang RJ. Electrical safety work control process and ISM. In: 2016 IEEE IAS Electrical Safety Workshop (ESW). IEEE; 2016. p. 1–6. DOI:10.1109/ESW.2016.7499700
19. Neitzel DK. Electrical safety for industrial and commercial power systems. In: 2016 IEEE IAS Electrical Safety Workshop (ESW).

IEEE; 2016. p. 1–8. DOI:10.1109/ESW.2016.7499711
20. Shinde A, S. Gurav A, P. Chaudhari B, K. Redasani V. A Review on Pharmaceutical Regulatory Authority of India, USA, UK, Australia. *Asian Journal of Research in Pharmaceutical Sciences.* 2024 Sep 19;243–8. DOI: 10.52711/2231-5659.2024.00040
21. Nwoke J. Regulatory Compliance and Risk Management in Pharmaceuticals and Healthcare. Int J Health Sci (Qassim). 2024 Sep 8;7(6):60–88. DOI:10.47941/ijhs.2223
22. B PG, R K. Pharmaceutical Inspection Co-operation Scheme: An Overview. Cureus. 2024 Sep 9; DOI: 10.7759/cureus.69043
23. Otitolaiye VO, Al-Naaimi M, Rasha Abdelrahim. Unlocking the Impact of Chemicals on the Health and Safety of Pharmaceutical Workers: A Concise Review. *Int J Occup Saf Health.* 2024 Aug 6;14(3):424–35. DOI:10.3126/ijosh.v14i3.64773
24. Shahriar MF. Drug Manufacturing and Management Process for Pharmaceutical Company. *GLS KALP: Journal of Multidisciplinary Studies.* 2024 Mar 18;3(4):31–8. DOI: https://doi.org/10.69974/glskalp.03.04.19
25. Veljanova Martinoski E. QUALITY RISK MANAGEMENT - REGULATORY FRAMEWORK. In: Quality for sustainable management - implementation of quality standards in practice. *United Association of Serbia for Quality*; 2024. p. 58–76.
26. Kumar AY. The New Three-Dimensional Safety Approach for the Implementation of Process Safety Management (PSM) and Improving Safety Aspects for the Pharmaceutical Industry in India – An Overview. *Indonesian Journal of Innovation and Applied Sciences (IJIAS)*. 2024 Apr 27;4(1):44–54. DOI:10.47540/ijias.v4i1.1269
27. Sussman V, Dutta S, Foisel J. Of People, Programs, and Priorities: The Impact of Organizational Culture in Industrial Research and Development Laboratories. ACS Chemical Health & Safety. 2023 Sep 25;30(5):223–35. DOI: https://pubs.acs.org/doi/10.1021/acs.chas.3c00052
28. Hazards and Safety Management in Pharmaceutical Industries: A Survey of Experts' Opinion. Turkish Online Journal of Qualitative Inquiry. 2023; DOI: https://doi.org/10.52783/tojqi.v11i3.10011
29. Ljubic M, Rakovic B, Dimitrov L, Garvanov I. Training of workers as an important safety measure for risk management. In: 2016 19th International Symposium on Electrical Apparatus and Technologies (SIELA). IEEE; 2016. p. 1–3. DOI:10.1109/SIELA.2016.7543022
30. M. Abdelhaleem Ali A, M. Alrobaian M. Strengths and weaknesses of current and future prospects of artificial intelligence-mounted technologies applied in the development of pharmaceutical products and services. *Saudi Pharmaceutical Journal.* 2024 May;32(5):102043. https://doi.org/10.1016/j.jsps.2024.102043
31. Chen W, Park SJ, Cheng TNH, Lau NWH, Khaw LF, Lee-Lane D, et al. Pharmaceutical Industry. In: Industry 40 Vision for Energy and Materials. Wiley; 2022. p. 313–37. DOI:10.1002/9781119695868.ch12
32. Malheiro V, Duarte J, Veiga F, Mascarenhas-Melo F. Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications. Pharmaceutics. 2023 Oct 28;15(11):2545. DOI: 10.3390/pharmaceutics15112545
33. Sha W, Guo Y, Yuan Q, Tang S, Zhang X, Lu S, et al. Artificial Intelligence to Power the Future of Materials Science and Engineering. Advanced Intelligent Systems. 2020 Apr 24;2(4). DOI:10.1002/aisy.201900143

How to cite this article: Aishwarya R Ghanwat, Kumudini R Pawar, Krutika S Nilwani, Shital P Narwade, Pratibha L Ayanar. A review on thermal and electrical hazards in the pharmaceutical industry. *International Journal of Research and Review*. 2025; 12(1): 415-426. DOI: *https://doi.org/10.52403/ijrr.20250150*

******